Minerva Neurosciences, Inc.
NERVMinerva Neurosciences, Inc. in brief
Minerva Neurosciences, Inc. is a listed company in the Biotechnology industry, based in Burlington, Massachusetts, USA. Its market value was $167 M on 30 September 2026, which makes it the 16,928th largest listed company in the world and the 3,258th largest in the USA on this site. It employs about 7 people and Remy Luthringer is its chief executive. Its shares trade under the symbol NERV (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Minerva Neurosciences, Inc.
We are a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system diseases.
Our lead product candidate, roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. In August 2022, we submitted a New Drug Application with the FDA for roluperidone for the treatment of negative symptoms in schizophrenia. On February 26, 2024, the FDA issued a Complete Response Letter regarding our NDA for roluperidone. Subsequent to the CRL, we have had multiple interactions with the FDA to confirm the design of an additional Phase 3 confirmatory clinical trial to address the deficiencies cited in the CRL and resubmit the NDA.
From the company's annual report filed with the US SEC: read the report
Minerva Neurosciences, Inc. timeline
- 2014
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 1 July 2014; shares registered for exchange trading on 23 June 2014.
Events of Minerva Neurosciences, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,958 (Jan 2020) · #3,688 (Jan 2021) · #5,071 (Jan 2022) · #5,472 (Dec 2022) · #4,120 (Jan 2024) · #1,585 (Mar 2026) · #3,051 (Aug 2026) · #3,235 (Sep 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- -14.8%
- Net margin
- —
- Operating margin
- —
- Return on equity
- —
- Liabilities / assets
- 238.6%
- R&D / revenue
- 53.5%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-15M | $-293M | — |
| Dec 2024 | — | — | $-22M | $1M | — |
| Dec 2023 | — | — | $-23M | $-30M | — |
| Dec 2022 | — | — | $-25M | $-32M | — |
| Dec 2021 | — | — | $-45M | $-50M | — |
| Dec 2020 | $41M | — | $2M | $2M | 4.7% |
| Dec 2019 | — | — | $-76M | $-72M | — |
| Dec 2018 | — | — | $-52M | $-50M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-14M | — | — | $-34.67 | — |
| Dec 2024 | $-20M | — | — | $0.19 | — |
| Dec 2023 | $-15M | — | — | $-4.61 | — |
| Dec 2022 | $-25M | $0M | $-25M | $-6.01 | — |
| Dec 2021 | $-25M | — | — | $-9.35 | — |
| Dec 2020 | $-34M | — | — | $0.05 | — |
| Dec 2019 | $-43M | — | — | $-1.85 | — |
| Dec 2018 | $-42M | — | — | $-1.29 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $101M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 6, 202610-QQuarterly report · period to Sep 2026
- Nov 6, 20268-KCurrent reportResults of operations
- Aug 12, 20268-KCurrent reportDirectors or officers changed
- Aug 7, 202610-QQuarterly report · period to Jun 2026
- Aug 7, 20268-KCurrent reportResults of operations
- Jun 4, 20268-KCurrent reportBylaws amended · Shareholder vote
- May 27, 20268-KCurrent reportMaterial agreement · Other events
- May 5, 202610-QQuarterly report · period to Mar 2026
- May 5, 20268-KCurrent reportResults of operations
- Apr 23, 2026DEF 14AProxy statement
- Apr 6, 20268-KCurrent reportOther events
- Apr 2, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure · Other events
Official filings of Minerva Neurosciences, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-15 M
- Net income
- $-293 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $98 M
- Total liabilities
- $234 M
- Total equity
- $-141 M
As of December-2025
Top 65 institutional investors in Minerva Neurosciences, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Federated Hermes, Inc. | 4,670,426 | 0 (0.00%) | 9.37% | $16 M | Nov 12, 2026 |
| 2 | Janus Henderson Group Ltd. | 4,481,877 | — | 8.99% | $15 M | Nov 16, 2026 |
| 3 | Vivo Capital, LLC | 4,322,747 | 0 (0.00%) | 8.67% | $14 M | Nov 13, 2026 |
| 4 | Balyasny Asset Management L.P. | 4,257,000 | 0 (0.00%) | 8.54% | $14 M | Nov 16, 2026 |
| 5 | Logos Global Management LP | 3,288,777 | 0 (0.00%) | 6.60% | $11 M | Nov 16, 2026 |
| 6 | BlackRock, Inc. | 2,451,359 | +210,781 (+9.41%) | 4.92% | $8 M | Nov 13, 2026 |
| 7 | Farallon Capital Management, L.L.C. | 2,365,000 | 0 (0.00%) | 4.75% | $8 M | Nov 16, 2026 |
| 8 | Foresite Capital Management VI LLC | 1,985,584 | 0 (0.00%) | 3.98% | $7 M | Nov 16, 2026 |
| 9 | Vanguard Capital Management LLC | 1,950,629 | +57,822 (+3.05%) | 3.91% | $7 M | Nov 13, 2026 |
| 10 | Ally Bridge Group (NY) LLC | 1,655,500 | -520,302 (-23.91%) | 3.32% | $6 M | Nov 16, 2026 |
| 11 | Spruce Street Capital LP | 1,655,500 | 0 (0.00%) | 3.32% | $6 M | Nov 13, 2026 |
| 12 | Adage Capital Partners GP, L.L.C. | 1,419,000 | 0 (0.00%) | 2.85% | $5 M | Nov 16, 2026 |
| 13 | Trails Edge Capital Partners, LP | 1,419,000 | 0 (0.00%) | 2.85% | $5 M | Nov 16, 2026 |
| 14 | Millennium Management LLC | 1,264,334 | +730,732 (+136.94%) | 2.54% | $4 M | Nov 16, 2026 |
| 15 | Seven Fleet Capital Management LP | 1,001,373 | 0 (0.00%) | 2.01% | $3 M | Nov 16, 2026 |
| 16 | Geode Capital Management, LLC | 977,069 | +2,833 (+0.29%) | 1.96% | $3 M | Nov 6, 2026 |
| 17 | DV Equities, LLC | 754,397 | 0 (0.00%) | 1.51% | $3 M | Nov 16, 2026 |
| 18 | Acuta Capital Partners, LLC | 729,500 | +20,000 (+2.82%) | 1.46% | $2 M | Nov 16, 2026 |
| 19 | State Street Corp | 609,735 | +184,820 (+43.50%) | 1.22% | $2 M | Nov 12, 2026 |
| 20 | Northern Trust Corp | 296,243 | +4,126 (+1.41%) | 0.59% | $1 M | Nov 16, 2026 |
| 21 | Vanguard Fiduciary Trust Co | 291,019 | -11,585 (-3.83%) | 0.58% | $1 M | Nov 13, 2026 |
| 22 | Vanguard Portfolio Management LLC | 248,054 | +13,300 (+5.67%) | 0.50% | $1 M | Nov 13, 2026 |
| 23 | Goldman Sachs Group Inc | 172,461 | +28,507 (+19.80%) | 0.35% | $1 M | Nov 16, 2026 |
| 24 | UBS Group AG | 148,714 | +106,506 (+252.34%) | 0.30% | $0 M | Nov 10, 2026 |
| 25 | Charles Schwab Investment Management Inc | 93,218 | -20,407 (-17.96%) | 0.19% | $0 M | Nov 16, 2026 |
Show all 65: investors 26 to 65
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Bank of New York Mellon Corp | 75,580 | 0 (0.00%) | 0.15% | $0 M | Nov 5, 2026 |
| 27 | Nuveen, LLC | 51,322 | +5,844 (+12.85%) | 0.10% | $0 M | Nov 10, 2026 |
| 28 | Invesco Ltd. | 44,068 | +4,379 (+11.03%) | 0.09% | $0 M | Nov 12, 2026 |
| 29 | Rhumbline Advisers | 43,101 | +13,234 (+44.31%) | 0.09% | $0 M | Nov 10, 2026 |
| 30 | Apella Capital, LLC | 42,250 | 0 (0.00%) | 0.08% | $0 M | Oct 8, 2026 |
| 31 | Renaissance Technologies LLC | 42,000 | -31,300 (-42.70%) | 0.08% | $0 M | Nov 12, 2026 |
| 32 | Bank Of America Corp /de/ | 33,620 | -4,112 (-10.90%) | 0.07% | $0 M | Nov 16, 2026 |
| 33 | XTX Topco Ltd | 30,246 | New | 0.06% | $0 M | Nov 16, 2026 |
| 34 | Morgan Stanley | 30,105 | +17,662 (+141.94%) | 0.06% | $0 M | Nov 13, 2026 |
| 35 | Deutsche Bank AG\ | 29,698 | -3,579 (-10.76%) | 0.06% | $0 M | Nov 6, 2026 |
| 36 | Price T Rowe Associates Inc /MD/ | 27,921 | 0 (0.00%) | 0.06% | $0 M | Nov 16, 2026 |
| 37 | Two Sigma Investments, LP | 25,675 | 0 (0.00%) | 0.05% | $0 M | Nov 16, 2026 |
| 38 | Citadel Advisors LLC | 23,385 | New | 0.05% | $0 M | Nov 16, 2026 |
| 39 | New York State Common Retirement Fund | 19,800 | 0 (0.00%) | 0.04% | $0 M | Nov 17, 2026 |
| 40 | Quadrature Capital Ltd | 18,872 | New | 0.04% | $0 M | Nov 13, 2026 |
| 41 | Jpmorgan Chase & Co | 17,136 | +3,021 (+21.40%) | 0.03% | $0 M | Nov 12, 2026 |
| 42 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 16,504 | +826 (+5.27%) | 0.03% | $0 M | Nov 16, 2026 |
| 43 | Vanguard Global Advisers, LLC | 15,491 | +156 (+1.02%) | 0.03% | $0 M | Nov 13, 2026 |
| 44 | Barclays PLC | 14,519 | +7,693 (+112.70%) | 0.03% | $0 M | Nov 6, 2026 |
| 45 | Police & Firemen's Retirement System of New Jersey | 10,346 | 0 (0.00%) | 0.02% | $0 M | Nov 9, 2026 |
| 46 | Wells Fargo & Company/mn | 9,763 | -20,506 (-67.75%) | 0.02% | $0 M | Nov 16, 2026 |
| 47 | BNP Paribas Financial Markets | 8,685 | +792 (+10.03%) | 0.02% | $0 M | Nov 12, 2026 |
| 48 | Citigroup Inc | 6,328 | -9,645 (-60.38%) | 0.01% | $0 M | Nov 4, 2026 |
| 49 | Tower Research Capital LLC (TRC) | 5,183 | +1,506 (+40.96%) | 0.01% | $0 M | Nov 16, 2026 |
| 50 | Royal Bank Of Canada | 4,583 | +3,347 (+270.79%) | 0.01% | $0 M | Nov 16, 2026 |
| 51 | Legal & General Group Plc | 3,320 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 52 | Ameritas Investment Partners, Inc. | 3,090 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 53 | Russell Investments Group, Ltd. | 3,055 | +333 (+12.23%) | 0.01% | $0 M | Nov 6, 2026 |
| 54 | FMR LLC | 1,911 | +1,674 (+706.33%) | 0.00% | $0 M | Nov 10, 2026 |
| 55 | Sterling Capital Management LLC | 988 | +692 (+233.78%) | 0.00% | $0 M | Oct 22, 2026 |
| 56 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 629 | New | 0.00% | $0 M | Nov 16, 2026 |
| 57 | Larson Financial Group LLC | 300 | -100 (-25.00%) | 0.00% | $0 M | Nov 5, 2026 |
| 58 | GAMMA Investing LLC | 290 | New | 0.00% | $0 M | Oct 8, 2026 |
| 59 | SBI Securities Co., Ltd. | 251 | 0 (0.00%) | 0.00% | $0 M | Oct 22, 2026 |
| 60 | Global Retirement Partners, LLC | 170 | New | 0.00% | $0 M | Nov 10, 2026 |
| 61 | Northwestern Mutual Wealth Management Co | 100 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 62 | Arax Advisory Partners | 74 | New | 0.00% | $0 M | Nov 12, 2026 |
| 63 | Allworth Financial LP | 33 | New | 0.00% | $0 M | Nov 17, 2026 |
| 64 | Caitong International Asset Management Co., Ltd | 7 | 0 (0.00%) | 0.00% | $0 M | Oct 29, 2026 |
| 65 | Rockefeller Capital Management L.P. | 2 | New | 0.00% | $0 M | Nov 13, 2026 |
Mutual funds holding Minerva Neurosciences, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Federated Hermes Kaufmann FundFederated Advisory Services Company | 2.59 M | $10 M | 5.2% | 0.21% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 1.32 M | $7 M | 2.6% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Federated Hermes Kaufmann Small Cap FundFederated Advisory Services Company | 1.71 M | $7 M | 3.4% | 0.24% | no change | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 651,463 | $4 M | 1.3% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 511,673 | $3 M | 1.0% | <0.01% | +5.5% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 370,368 | $1 M | 0.74% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 220,170 | $1 M | 0.44% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Federated Hermes Kaufmann Small Cap FundFederated Advisory Services Company | 269,435 | $1 M | 0.54% | 0.04% | no change | Jul 31, 2026 |
| 🇺🇸 Federated Hermes Kaufmann FundFederated Advisory Services Company | 225,722 | $1 M | 0.45% | 0.02% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 152,543 | $1 M | 0.31% | <0.01% | +784% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 113,626 | $1 M | 0.23% | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 92,757 | $1 M | 0.19% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 81,021 | $0 M | 0.16% | <0.01% | +308% | May 31, 2026 |
| 🇺🇸 Federated Hermes Kaufmann Fund IIFederated Advisory Services Company | 70,524 | $0 M | 0.14% | 0.35% | — | Jun 30, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 63,647 | $0 M | 0.13% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 82,625 | $0 M | 0.17% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 65,680 | $0 M | 0.13% | <0.01% | +875% | May 31, 2026 |
| 🇺🇸 Federated Hermes Kaufmann FundFederated Advisory Services Company | 75,000 | $0 M | 0.15% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Federated Hermes Kaufmann Small Cap FundFederated Advisory Services Company | 70,950 | $0 M | 0.14% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 34,308 | $0 M | 0.07% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 45,478 | $0 M | 0.09% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 26,100 | $0 M | 0.05% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 27,931 | $0 M | 0.06% | <0.01% | +209% | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 23,025 | $0 M | 0.05% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 22,245 | $0 M | 0.04% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 31,000 | $0 M | 0.06% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 18,555 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 17,542 | $0 M | 0.04% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 14,657 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 14,200 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 16,244 | $0 M | 0.03% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 9,204 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 7,573 | $0 M | 0.02% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 7,268 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 7,199 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 9,207 | $0 M | 0.02% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 5,318 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 5,133 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Federated Hermes Kaufmann Fund IIFederated Advisory Services Company | 4,769 | $0 M | <0.01% | 0.02% | — | Jun 30, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 4,403 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 4,395 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Federated Hermes Kaufmann Fund IIFederated Advisory Services Company | 4,050 | $0 M | <0.01% | 0.02% | — | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 3,445 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 3,090 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 4,206 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 3,987 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 2,722 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 2,633 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 2,098 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 2,866 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 1,640 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 1,390 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 1,390 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 1,793 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 1,255 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 859 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 800 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 57 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Minerva Neurosciences, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Remy LuthringerCEO, Director | Sell | -3,641 | $3.760 | $14 K | 68,994 | Form 4 |
| filed | Geoff RacePresident | Sell | -22,082 | $3.850 | $85 K | 51,324 | Form 4 |
| filed | Remy LuthringerCEO, Director | Sell | -23,753 | $3.850 | $91 K | 72,635 | Form 4 |
| filed | Frederick W. AhlholmSVP, CFO and Secretary | Sell | -3,580 | $4.480 | $16 K | 17,518 | Form 4 |
| filed | Geoff RacePresident | Grant or award | +46,987 | — | — | 73,406 | Form 4 |
| filed | Remy LuthringerCEO, Director | Grant or award | +88,077 | — | — | 96,388 | Form 4 |
| filed | Frederick W. AhlholmSVP, CFO and Secretary | Grant or award | +19,843 | — | — | 21,098 | Form 4 |
| filed | David KupferDirector | Sell | -55,635 | $0.880 | $49 K | 163,553 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Minerva Neurosciences, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 3.5-for-1 split
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q4 2017 | Q4 2017 | $0M |
Trading halts
- 2025-11-17 15:13 UTC, code LUDP, resumed 15:18 UTC
Fails to deliver
- : 1,768 shares at $3.35
- : 1,735 shares at $3.81
- : 654 shares at $3.69
- : 10,663 shares at $3.49
- : 4,095 shares at $3.83
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Minerva Neurosciences, Inc. scorecard#
Passes 1 of the 11 checks that could be worked out. Fiscal year 2025; market cap of Sep 30, 2026.
Valuation0 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-14.8%Free cash flow is -14.8% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-34.67 vs 0.19Diluted EPS -34.67 in fiscal 2025 against 0.19 the year before (report's currency).
- ✗Net income higher than five years earlier-$293 M-$293 M in fiscal 2025 against $2 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$293 MNet income -$293 M in fiscal 2025.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities36.3×Current ratio 36.29 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year11.8%Diluted shares up 11.8% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Minerva Neurosciences, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | — | 0—— | 0—— | 0—— | 0−100%— | 41—100% | 0—— | 0—— | 0—— | — | |
| Research and development | 5.8−51.6%— | 12−6.3%— | 13−13.3%— | 15−54.3%— | 32+45.4%— | 22−62.1%53.5% | 58+66.6%— | 35+15.3%— | 30+48.0%— | 20—— | |
| General and administrative | 9.3−6.1%— | 9.9−4.5%— | 10−1.6%— | 11−20.6%— | 13−22.9%— | 17−2.5%42.0% | 18+5.3%— | 17+54.3%— | 11+11.9%— | 9.8—— | |
| Operating expenses | 15−30.9%— | 22−5.5%— | 23−8.4%— | 25−44.4%— | 45+15.3%— | 39−48.2%95.5% | 76+46.7%— | 52+25.6%— | 41+36.4%— | 30—— | |
| Operating income | −15—— | −22—— | −23—— | −25—— | −45−2557%— | 1.8—4.5% | −76—— | −52—— | −41—— | −30—— | |
| Interest and finance income | 0.9−25.5%— | 1.3−11.5%— | 1.4+158%— | 0.6+3272%— | 0.0−89.8%— | 0.2−88.9%0.4% | 1.5−13.0%— | 1.7+77.7%— | 0.9+375%— | 0.2—— | |
| Income before tax | — | — | — | −32—— | −52−2764%— | 1.9—4.7% | −74—— | −50—— | −41—— | −31—— | |
| Income tax | — | — | — | — | −1.8—— | — | −2.3—— | 0—— | −9.4r−9.4—— | 0—— | |
| Net income including minority interests | −293−20493%— | 1.4—— | −30—— | −32—— | −50−2671%— | 1.9—4.7% | −72—— | −50—— | −32—— | — | |
| Net income attributable to shareholders | −293−20493%— | 1.4—— | −30—— | −32—— | −50−2671%— | 1.9—4.7% | −72—— | −50—— | −32—— | −31—— | |
| Earnings per share, basic | -34.67−18347%— | 0.19—— | -4.61—— | -6.01—— | -9.35r-1.17−18800%— | 0.05—— | -1.85—— | -1.29—— | -0.83—— | -0.99—— | |
| Earnings per share, diluted | -34.67−18347%— | 0.19—— | -4.61—— | -6.01—— | -9.35r-1.17−18800%— | 0.05—— | -1.85—— | -1.29—— | -0.83—— | -0.99—— | |
| Shares, weighted average (basic) | 8.5+11.8%— | 7.6+16.3%— | 6.5+21.8%— | 5.3−0.0%— | 5.3r43−86.9%— | 41+4.6%— | 39—— | — | — | — | |
| Shares, weighted average (diluted) | 8.5+11.7%— | 7.6+16.4%— | 6.5+21.8%— | 5.3−0.0%— | 5.3r43−86.9%— | 41+4.9%— | 39+0.6%— | 39+2.3%— | 38+20.4%— | 32—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 82+285%84.0% | 21−47.8%57.5% | 41+13.4%71.9% | 36−40.6%65.5% | 61+140%78.8% | 25+18.4%44.0% | 21−57.4%27.6% | 50+92.8%36.1% | 26−68.6%14.2% | 83—62.4% | |
| Short-term investments | — | — | — | — | — | — | 24−35.3%31.5% | 38−63.0%27.1% | 102—55.6% | — | |
| Current assets | 83+273%84.8% | 22−47.0%60.0% | 42+4.6%73.8% | 40−35.4%72.9% | 62+127%80.7% | 27−41.8%47.6% | 47−47.6%60.8% | 90−30.5%64.7% | 130+54.5%70.5% | 84—63.1% | |
| Property, plant and equipment | 0−100%0.0% | 0.0−50.0%0.0% | 0.0−33.3%0.0% | 0.0—0.0% | — | — | 0.0−52.2%0.0% | 0.0−34.3%0.0% | 0.1+428%0.0% | 0.0—0.0% | |
| Right-of-use (leased) assets | — | — | — | — | — | 0.1−61.1%0.2% | 0.3—0.3% | — | — | — | |
| Goodwill | 150.0%15.2% | 150.0%40.0% | 150.0%26.1% | 150.0%27.0% | 150.0%19.3% | 150.0%25.8% | 150.0%19.2% | 150.0%10.7% | 150.0%8.1% | 15—11.2% | |
| Other intangible assets | — | — | — | — | — | 150.0%26.4% | 15−55.6%19.6% | 340.0%24.6% | 340.0%18.6% | 34—25.7% | |
| Total assets | 98+164%100% | 37−34.7%100% | 57+3.3%100% | 55−28.6%100% | 77+33.8%100% | 58−25.6%100% | 77−44.3%100% | 139−24.3%100% | 184+38.2%100% | 133—100% | |
| Accounts payable | 0.6−60.2%0.7% | 1.6−10.9%4.3% | 1.8+86.2%3.2% | 1.0−47.7%1.8% | 1.9+86.1%2.4% | 1.0−57.0%1.7% | 2.3+28.7%3.0% | 1.8+25.4%1.3% | 1.4−2.2%0.8% | 1.5—1.1% | |
| Current liabilities | 2.3−19.3%2.3% | 2.8−15.1%7.6% | 3.3+142%5.9% | 1.4−51.1%2.5% | 2.8−10.8%3.7% | 3.2−52.3%5.5% | 6.6+83.7%8.6% | 3.6−47.2%2.6% | 6.8−29.4%3.7% | 9.7—7.3% | |
| Lease liabilities (non-current) | — | — | — | — | — | — | 0.1—0.1% | — | — | — | |
| Total liabilities | 234+272%239% | 63−26.4%169% | 85+13.6%150% | 75+8.6%136% | 69+1293%89.7% | 5.0−90.0%8.6% | 50+1.7%64.2% | 49−6.2%35.1% | 52+93.2%28.4% | 27—20.3% | |
| Retained earnings | −689—−703% | −395—−1064% | −397—−697% | −367—−666% | −335—−434% | −285—−494% | −287—−370% | −215—−154% | −164—−89.5% | −133—−99.9% | |
| Shareholders' equity | −141—−144% | −26—−69.2% | −28—−50.0% | −20−351%−36.4% | 8.0−84.9%10.3% | 53+89.6%91.4% | 28−69.2%35.8% | 90−31.4%64.9% | 132+24.2%71.6% | 106—79.7% | |
| Total liabilities and equity | 98+164%100% | 37−34.7%100% | 57+3.3%100% | 55−28.6%100% | 77+33.8%100% | 58−25.6%100% | 77−44.3%100% | 139−24.3%100% | 184+38.2%100% | 133—100% | |
| Shares outstanding | 43+519%— | 7.00.0%— | 7.0+31.0%— | 5.3−0.0%— | 5.3r43−87.5%— | 43+9.3%— | 39+0.4%— | 39+0.5%— | 39+10.6%— | 35—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.00.0%— | 0.00.0%— | 0.0—— | — | — | 0.0−8.3%0.0% | 0.00.0%— | 0.0+57.4%— | 0.0−32.9%— | 0.0—— | |
| Share-based compensation | 1.3+0.1%— | 1.3−32.7%— | 2.0−52.1%— | 4.1−21.3%— | 5.2−46.2%— | 9.7+5.8%23.6% | 9.2+12.1%— | 8.2+62.6%— | 5.0+40.9%— | 3.6—— | |
| Cash from operating activities | −14—— | −20—— | −15—— | −25—— | −25—— | −34—−82.1% | −43—— | −42−1456%— | 3.1—— | −26—— | |
| Capital expenditure | — | — | — | −0.0—— | — | — | — | — | −0.1—— | — | |
| Cash from investing activities | 0—— | 0—— | 0—— | −0.0—— | — | 25+74.1%59.6% | 14−79.7%— | 69—— | −107−702%— | 18—— | |
| Shares bought back | — | — | — | — | — | — | — | — | −0.0—— | — | |
| Cash from financing activities | 74—— | — | 20—— | −0.0−100%— | 60+353%— | 13+2422%32.2% | 0.5—— | −3.3−107%— | 47−38.4%— | 77—— | |
| Change in cash | 61—— | −20−506%— | 4.8—— | −25−170%— | 35+797%— | 3.9—9.6% | −29−219%— | 24—— | −57—— | — | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 20+255%— | 5.2+457%— | 7.2+454%— | 5.3+286%— | 2.2*+9.6%— | 0.9−51.0%— | 1.3−66.4%— | 1.4−67.3%— | 2.0*−58.0%— | 1.9—— | 3.9—— | 4.2—— | 4.7*—— | |
| General and administrative | 22+142%— | 4.3+123%— | 3.5+66.4%— | 11+349%— | 2.8*+10.6%— | 1.9−22.6%— | 2.1−14.1%— | 2.5+1.0%— | 2.5*+3.6%— | 2.5—— | 2.4—— | 2.5—— | 2.5*—— | |
| Operating expenses | 42+185%— | 9.4+232%— | 11+215%— | 17+327%— | 5.0*+10.2%— | 2.8−34.9%— | 3.4−46.3%— | 3.9−41.6%— | 4.5*−36.9%— | 4.4—— | 6.3—— | 6.7—— | 7.2*—— | |
| Operating income | −42—— | −9.4—— | −11—— | −17—— | −5.0*—— | −2.8—— | −3.4—— | −3.9—— | −4.5*—— | −4.4—— | −6.3—— | −6.7—— | −7.2*—— | |
| Interest and finance income | 2.3+264%— | 0.6+450%— | 0.6+317%— | 0.6+298%— | 0.5*+128%— | 0.1−66.0%— | 0.1−62.1%— | 0.2−55.8%— | 0.2*−33.2%— | 0.3—— | 0.4—— | 0.4—— | 0.4*—— | |
| Net income including minority interests | −291—— | 101*—— | 17*—— | −125—— | −284*—— | −2.7*−112%— | −3.3*—— | −3.8—— | −4.3*—— | 23*—— | −8.2*—— | −8.6—— | −9.0*—— | |
| Net income attributable to shareholders | −291—— | 101—— | 17—— | −125—— | −284*—— | −2.7−112%— | −3.3—— | −3.8—— | −4.3*—— | 23—— | −8.2—— | −8.6—— | −9.0*—— | |
| Earnings per share, basic | — | 1.94—— | 0.36—— | -2.86—— | — | -0.36−112%— | -0.43—— | -0.50—— | — | 2.97—— | -1.09—— | -1.13—— | — | |
| Earnings per share, diluted | — | -0.19—— | -0.14—— | -2.86—— | — | -0.36−112%— | -0.43—— | -0.50—— | — | 2.97—— | -1.09—— | -1.13—— | — | |
| Shares, weighted average (basic) | 49+551%— | 49+551%— | 47+516%— | 44+480%— | — | 7.60.0%— | 7.60.0%— | 7.60.0%— | — | 7.6—— | 7.6—— | 7.6—— | — | |
| Shares, weighted average (diluted) | 75+894%— | 75+894%— | 79+945%— | 44+480%— | — | 7.60.0%— | 7.60.0%— | 7.60.0%— | — | 7.6—— | 7.6—— | 7.6—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 20—20.6% | 20+64.5%20.6% | 25+61.7%25.9% | 33+88.9%34.7% | 82+285%84.0% | 12−53.7%43.7% | 15−50.6%50.1% | 17−50.3%52.7% | 21−47.8%57.5% | 27—62.0% | 31—66.7% | 35—68.9% | 41—71.9% | |
| Short-term investments | 57—57.7% | 57—57.7% | 51—53.2% | 45—48.3% | — | — | — | — | — | — | — | — | — | |
| Current assets | 83—84.9% | 83+541%84.9% | 80+413%83.9% | 79+341%84.1% | 83+273%84.8% | 13−53.4%46.3% | 16−50.5%51.1% | 18−49.7%54.7% | 22−47.0%60.0% | 28—65.3% | 31—67.9% | 36—70.5% | 42—73.8% | |
| Property, plant and equipment | — | — | — | — | 0−100%0.0% | 0.0−80.0%0.0% | 0.0−66.7%0.0% | 0.0−57.2%0.0% | 0.0−50.0%0.0% | 0.0—0.0% | 0.0—0.0% | 0.0—0.0% | 0.0—0.0% | |
| Goodwill | 15—15.1% | 150.0%15.1% | 150.0%15.6% | 150.0%15.8% | 150.0%15.2% | 150.0%52.9% | 150.0%48.9% | 150.0%45.3% | 150.0%40.0% | 15—34.7% | 15—32.1% | 15—29.4% | 15—26.1% | |
| Total assets | 98—100% | 98+250%100% | 95+213%100% | 94+187%100% | 98+164%100% | 28−34.4%100% | 30−34.3%100% | 33−35.1%100% | 37−34.7%100% | 43—100% | 46—100% | 51—100% | 57—100% | |
| Accounts payable | 0.7—0.7% | 0.7−30.8%0.7% | 1.4+61.4%1.5% | 2.1+231%2.3% | 0.6−60.2%0.7% | 0.9+70.7%3.4% | 0.9+8.3%2.9% | 0.6−55.4%2.0% | 1.6−10.9%4.3% | 0.6—1.3% | 0.8—1.8% | 1.4—2.8% | 1.8—3.2% | |
| Current liabilities | 2.5—2.6% | 2.5−5.5%2.6% | 4.0+56.5%4.2% | 4.5+130%4.8% | 2.3−19.3%2.3% | 2.7−40.4%9.5% | 2.5−39.8%8.3% | 1.9−31.2%5.9% | 2.8−15.1%7.6% | 4.5—10.5% | 4.2—9.1% | 2.8—5.6% | 3.3—5.9% | |
| Total liabilities | 184—187% | 184+194%187% | 297+374%312% | 343+454%365% | 234+272%239% | 63−2.8%223% | 63−31.1%206% | 62−28.9%189% | 63−26.4%169% | 64—151% | 91—196% | 87—172% | 85—150% | |
| Retained earnings | −696—−708% | −696—−708% | −797—−838% | −814—−866% | −689—−703% | −405—−1442% | −402—−1323% | −399—−1217% | −395—−1064% | −391—−914% | −414—−894% | −405—−803% | −397—−697% | |
| Shareholders' equity | −98—−99.2% | −98—−99.2% | −213—−224% | −254—−270% | −141—−144% | −35—−123% | −32—−106% | −29—−88.9% | −26—−69.2% | −22—−50.6% | −44—−96.1% | −37—−72.4% | −28—−50.0% | |
| Total liabilities and equity | 98—100% | 98+250%100% | 95+213%100% | 94+187%100% | 98+164%100% | 28−34.4%100% | 30−34.3%100% | 33−35.1%100% | 37−34.7%100% | 43—100% | 46—100% | 51—100% | 57—100% | |
| Shares outstanding | 50—— | 50+613%— | 47+575%— | 44+527%— | 43+519%— | 7.00.0%— | 7.00.0%— | 7.00.0%— | 7.00.0%— | 7.0—— | 7.0—— | 7.0—— | 7.0—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | — | — | — | — | 0.0*0.0%— | 0.0*0.0%— | 0.0*−0.1%— | 0.0+0.1%— | 0.0*−0.1%— | 0.0*—— | 0.0*—— | 0.0—— | 0.0*—— | |
| Share-based compensation | 15+1210%— | 3.2+1076%— | 2.3+662%— | 8.7+2831%— | 0.5*+83.9%— | 0.3−11.3%— | 0.3−9.4%— | 0.3−32.3%— | 0.2*−59.1%— | 0.3—— | 0.3—— | 0.4—— | 0.6*—— | |
| Cash from operating activities | −31—— | −8.1*—— | −13*—— | −5.4—— | −4.5*—— | −2.9*—— | −2.0*—— | −4.1—— | −5.2*—— | −4.4*—— | −3.9*—— | −6.1—— | −6.0*—— | |
| Cash from investing activities | −56—— | −5.7*—— | −4.8*—— | −45—— | 0*—— | 0*—— | 0*—— | 0—— | 0*—— | 0*—— | 0*—— | 0—— | 0*—— | |
| Cash from financing activities | 95—— | 9.4*—— | 10*—— | 1.1—— | 74*—— | −0.0*—— | 0*—— | 0—— | — | — | 0*—— | 0—— | 0*—— | |
| Change in cash | 7.9—— | −4.4*—— | −8.0*—— | −50—— | 70*—— | −3.0*—— | −2.0*—— | −4.1—— | −5.2*—— | −4.4*—— | −3.9*—— | −6.1—— | −6.0*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at Minerva Neurosciences, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Dr. Remy Luthringer | $9.4 M | $9.9 M | $4.4 M | $253 |
| 2024Dr. Remy Luthringer | $1.2 M | $1.3 M | $837 K | $140 |
| 2023Dr. Remy Luthringer | $1.8 M | $2.1 M | $1.2 M | $387 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Minerva Neurosciences, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Delisting notice 2 · Directors and officers 5 · Material agreement 2 · Unregistered share sale 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 2 · Shareholder vote 3 · Results announced 4
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Shareholder rights changedBylaws or fiscal year changedShareholder vote | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Material agreementUnregistered share saleBylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Delisting notice | 8-K | |
| Directors and officers | 8-K | |
| Delisting notice | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 6, 2026
Acquisitions and funding#
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Minerva Neurosciences, Inc. compares in Biotechnology
- Market cap$167 M · higher than 42% of 726
- FCF yield-14.8% · higher than 50% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Minerva Neurosciences, Inc.🇺🇸 | $167 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Sep 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Minerva Neurosciences, Inc.? Verify and update this profile — free
Show Minerva Neurosciences, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.